CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can switching PARP inhibitors outsmart cancer? new trial aims to find out
Disease control Recruiting nowThis study is testing a drug called talazoparib in people with advanced solid tumors that have specific DNA repair gene mutations. The goal is to see if this PARP inhibitor can shrink tumors or slow their growth, even in patients who have already tried a similar drug. About 36 ad…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:34 UTC
-
New hope for tough prostate cancer: two chemo drugs may work better than one
Disease control Recruiting nowThis study tests whether adding a second chemotherapy drug (carboplatin) to the standard chemo (cabazitaxel) helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 528 participants will be randomly assigned to receive either cabaz…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 26, 2026 03:29 UTC
-
Second dose of radioactive drug shows promise for tough prostate cancer
Disease control Recruiting nowThis study looks at whether giving a second course of a radioactive drug called 177Lu-PSMA-617 can help people with advanced prostate cancer that no longer responds to hormone therapy. Participants must have already benefited from an initial round of this treatment. The goal is t…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:28 UTC
-
Could fewer doses of targeted radiation control prostate cancer just as well?
Disease control Recruiting nowThis study is for people with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares the standard 6 cycles of a targeted radiation drug (Lu-177 PSMA-617) against stopping after 5 cycles, to see if the shorter course can control t…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 03:26 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial tests a new treatment for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. Some participants will als…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 03:05 UTC
-
New combo aims to boost radiation therapy for advanced prostate cancer
Disease control Recruiting nowThis study tests whether giving a drug called abemaciclib before a targeted radiation therapy (177Lu-PSMA-617) can make the radiation work better for men with advanced prostate cancer that has stopped responding to other treatments. About 30 participants will receive the combinat…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
Could High-Dose testosterone boost prostate cancer treatment?
Disease control Recruiting nowThis study tests whether giving high levels of testosterone alongside chemotherapy or a targeted radiation drug can help men with advanced prostate cancer that has stopped responding to standard hormone therapy. About 69 participants will receive one of three treatment combinatio…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New combo therapy aims to stall Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests two drugs, cabozantinib and atezolizumab, in 33 men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. Cabozantinib blocks enzymes that help cancer grow, while atezolizumab boosts the immune system to attack tumors.…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Testosterone therapy shows promise for Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests a treatment called bipolar androgen therapy for men with advanced prostate cancer that no longer responds to standard hormone therapy and has spread. The approach rapidly switches testosterone levels from very low to very high to shock cancer cells an…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New combo drug trial targets tough prostate cancer
Disease control Recruiting nowThis study tests a combination of two drugs, ruxolitinib and enzalutamide, in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find the safest dose and see if the combination can shrink tumors or lower PSA levels. About 2…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether a new cell therapy (STEAP1 CART) combined with the drug enzalutamide is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments. About 48 participants will receive their own immune cells, modi…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New combo aims to make resistant prostate cancer cells visible to targeted radiation
Disease control Recruiting nowThis study tests whether the drug vorinostat can help men with a type of advanced prostate cancer that has low levels of a specific marker (PSMA). The marker is needed for a radioactive therapy called 177Lu-PSMA-617 to work. By giving vorinostat first, the hope is to increase PSM…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
Freezing tumors may boost radiation pain relief for bone metastases
Symptom relief Recruiting nowThis study tests whether adding cryoablation (freezing cancer cells) to standard radiation therapy provides better pain relief for people with cancer that has spread to the bones. About 40 adults with certain advanced cancers (like prostate, kidney, or colorectal) will be enrolle…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 22, 2026 13:50 UTC
-
DNA-Guided prostate cancer trial aims to match patients with targeted drugs
Knowledge-focused Recruiting nowThis study tests whether analyzing the DNA and RNA of a patient's prostate cancer can help doctors pick the most effective treatment. About 474 men with advanced, treatment-resistant prostate cancer will have their tumor tissue tested for specific genetic changes. Based on the re…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated May 26, 2026 03:30 UTC
-
Can DNA glitches predict prostate cancer treatment success?
Knowledge-focused Recruiting nowThis study looks at men with advanced prostate cancer that has spread to the bones. Researchers want to see if certain DNA repair problems make the drug radium-223 work better. About 48 men will take part, and their response will be measured by blood tests. The goal is to help do…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 26, 2026 03:28 UTC
-
Biopsies reveal secrets of prostate cancer resistance
Knowledge-focused Recruiting nowThis study looks at why some prostate cancers become resistant to a treatment called 177Lu-PSMA, which delivers radiation directly to cancer cells. Researchers will take small tissue samples (biopsies) from tumors in 30 men with advanced prostate cancer that has spread. The goal …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 22, 2026 13:50 UTC